Table 1. Cohort demographics for primary and validation cohorts investigated by genome-wide association for the outcome of peak serum creatinine during vancomycin therapy.
| Primary Cohort | Marshfield Validation Cohort | Mayo Validation Cohort | VGER Validation Cohort | |
|---|---|---|---|---|
| (N = 489) | (N = 343) | (N = 59) | (N = 37) | |
| Age (years)* | 55 (43–65) | 64 (53–75) | 70 (58–75) | 54 (45–66) |
| Male^ | 289 (59%) | 197 (57%) | 39 (66%) | 17 (46%) |
| Weight (kg)* | 81 (66–97) | 86 (68–103) | 88 (74–100) | 82 (68–96) |
| Height (m)* | 173 (165–180) | 168 (161–177) | 170 (162–182) | 175 (165–180) |
| Vancomycin Dose (mg)* | 1000 (1000–1000) | 1200 (1000–1500) | 1400 (1100–1500) | 1000 (1000–1000) |
| Vancomycin Dosing Interval (h)* | 12 (12–12) | 12 (12–24) | 12 (12–24) | 12 (8–12) |
| Vancomycin Trough (mcg/mL)* | 10 (7–16) | 11 (8–16) | 12 (10–15) | 12 (7–17) |
| Baseline Creatinine (mg/dL)* | 0.7 (0.6–0.9) | 0.8 (0.6–1.0) | 0.9 (0.8–1.0) | 0.8 (0.6–1.1) |
| Creatinine at Vancomycin Start (mg/dL)* | 0.9 (0.7–1.1) | 0.9 (0.7–1.1) | 1.0 (0.9–1.2) | 0.8 (0.7–1.0) |
| 24-hour Loop Diuretic Dose (mg)* | 0 (0–10) | 0 (0–0) | 0 (0–20) | 0 (0–0) |
| Loop Diuretic Exposure^ | 134 (27%) | 33 (10%) | 23 (39%) | 2 (5%) |
| Number of Non-loop Diuretics^ | ||||
| 0 | 423 (87%) | 314 (92%) | 41 (69%) | 30 (81%) |
| 1 or more | 66 (13%) | 29 (8%) | 18 (31%) | 7 (19%) |
| Number of Nephrotoxic Drugs^ | ||||
| 0 | 164 (34%) | 225 (66%) | 8 (14%) | 16 (43%) |
| 1 | 190 (39%) | 50 (15%) | 24 (41%) | 10 (27%) |
| 2 or more | 135 (28%) | 68 (20%) | 27 (46%) | 11 (30%) |
| Peak Creatinine (mg/dL) | 1.0 (0.8–1.3) | 1.0 (0.8–1.4) | 1.1 (0.9–1.4) | 0.9 (0.7–1.0) |
*Median (interquartile range)
^N, %.